Advertisement
Advertisement
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges
PremiumCompany AnnouncementsKymera Therapeutics’ Earnings Call Highlights Growth and Challenges
9d ago
Kymera Therapeutics price target raised to $73 from $70 at Morgan Stanley
Premium
The Fly
Kymera Therapeutics price target raised to $73 from $70 at Morgan Stanley
9d ago
Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release
Premium
Ratings
Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release
9d ago
KYMR Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsKYMR Upcoming Earnings Report: What to Expect?
12d ago
Kymera Therapeutics price target raised to $72 from $54 at BofA
Premium
The Fly
Kymera Therapeutics price target raised to $72 from $54 at BofA
13d ago
Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
Premium
Ratings
Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
17d ago
Kymera Therapeutics price target raised to $75 from $59 at BTIG
PremiumThe FlyKymera Therapeutics price target raised to $75 from $59 at BTIG
23d ago
Kymera Therapeutics initiated with an Outperform at Mizuho
Premium
The Fly
Kymera Therapeutics initiated with an Outperform at Mizuho
24d ago
Kymera Therapeutics price target raised to $80 from $60 at Citi
Premium
The Fly
Kymera Therapeutics price target raised to $80 from $60 at Citi
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100